Tüdőrák: vizsgálatok itt: Kína

In Kína 1144 Also abroad 2746

1144 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.

2. fázisTaking people
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Beijing, Fuzhou, Harbin, Linyi, Nanchang, Nanning, Ürümqi, Wuhan, Xi'an, Zhengzhou
Életkor
18 év and over
People
150 worldwide
Run by
AbbVie
See details and how to joinNCT06568939
No phaseNot yet taking people in Kína
Pulsed Field Ablation for the Treatment of Malignant Lung Tumors
Where
Shanghai
Életkor
18 év and over
People
15
Run by
Shanghai Chest Hospital
See details and how to joinNCT07889297
2. fázisNot yet taking people in Kína
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
Where
Shanghai
Életkor
18 év to 75 év
People
64
Run by
Ruijin Hospital
See details and how to joinNCT07890636
2. fázisTaking people
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Where
Beijing, Changchun, Guangzhou, Xi’an
Életkor
18 év and over
People
320 worldwide
Run by
Pfizer
See details and how to joinNCT04606446
1/2. fázisTaking people
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Where
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taizhou, Tianjin, Wuhan, Xi’an, Xinxiang, Zhengzhou
Életkor
18 év and over
People
862 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT05914116
No phaseTaking people
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
Where
Beijing
Életkor
18 év and over
People
3000
Run by
AstraZeneca
See details and how to joinNCT07316062
No phaseTaking people
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
Where
Guangzhou
Életkor
18 év and over
People
265
Run by
Guangdong Association of Clinical Trials
See details and how to joinNCT07696832
2. fázisNot yet taking people in Kína
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
Where
Beijing
Életkor
18 év and over
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT07885709
1. fázisTaking people
Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer
Where
Changsha
Életkor
18 év to 75 év
People
18
Run by
Second Xiangya Hospital of Central South University
See details and how to joinNCT07886047
1. fázisTaking people
Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
Where
Changsha
Életkor
18 év to 75 év
People
9
Run by
Second Xiangya Hospital of Central South University
See details and how to joinNCT07886229
3. fázisTaking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiangxi, Jinan, Kunming, Linyi, Nanchang, Nanjing, Shanghai, Shanxi, Shenzhen, Tianjin, Weifang, Wuhan, Xiamen, Xi’an, Xinxiang, Yangzhou, Zhengzhou
Életkor
18 év and over
People
695 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06801834
No phaseNot yet taking people in Kína
Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
Where
Beijing, Changsha
Életkor
18 év to 75 év
People
1050
Run by
Beijing Chao Yang Hospital
See details and how to joinNCT07882628
1/2. fázisTaking people
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Where
Shanghai
Életkor
18 év to 75 év
People
265
Run by
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
See details and how to joinNCT06283719
2. fázisTaking people
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
Where
Jinan
Életkor
18 év to 75 év
People
120
Run by
Shanghai Hengrui Pharmaceutical Co., Ltd.
See details and how to joinNCT07798947
1. fázisTaking people
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Where
Beijing, Ch’ang-ch’un, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xiamen, Xi’an, Zhengzhou
Életkor
18 év and over
People
339 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT06179069
1/2. fázisTaking people
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Where
Beijing, Changsha, Chongqing, Harbin, Jinan, Nanchang, Shenyang, Zhengzhou
Életkor
18 év to 75 év
People
480 worldwide
Run by
Avenzo Therapeutics, Inc.
See details and how to joinNCT07038343
3. fázisTaking people
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Where
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Heilongjiang, Jinan, Linyi, Nanchang, Naning, Nanjing, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xiamen, Xi’an, Zhengzhou
Életkor
18 év and over
People
480 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146
4. fázisTaking people
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
Where
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou
Életkor
18 év and over
People
100
Run by
AstraZeneca
See details and how to joinNCT07279935
No phaseTaking people
Barriers and Facilitators of Persistence With Adjuvant Osimertinib
Where
Beijing
Életkor
18 év and over
People
100
Run by
AstraZeneca
See details and how to joinNCT07542210
2. fázisNot yet taking people in Kína
Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study
Where
Changsha
Életkor
18 év and over
People
27
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT07878871
2. fázisTaking people
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Where
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Mianyang, Nanchang, Shantou, Shenyang, Wuhan, Zhengzhou, Zhuhai
Életkor
18 év and over
People
278 worldwide
Run by
AstraZeneca
See details and how to joinNCT07098338 · EU 2025-524843-11-00
No phaseTaking people
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
Where
Beijing
Életkor
18 év and over
People
50
Run by
Peking University Third Hospital
See details and how to joinNCT07760012
No phaseTaking people
Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC
Where
Shanghai
Életkor
18 év and over
People
52
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07874581
2. fázisNot yet taking people in Kína
Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
Where
Hangzhou
Életkor
18 év and over
People
120
Run by
Bing Xia
See details and how to joinNCT07875465
1. fázisNot yet taking people in Kína
Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation
Where
Beijing, Hangzhou
Életkor
18 év to 75 év
People
66
Run by
Neowise Biotechnology
See details and how to joinNCT07875920